Navigation Links
CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas
Date:6/5/2009

portant implications for our ability to develop an effective treatment for swine flu and other H1N1 flu viruses."

L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology.

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R) which is being readied for a global Phase III trial. The Company has operations in Vienna, Virginia, and Baltimore, Maryland.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include: an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Isis and Collaborators Present New Research at the ATVB Annual Conference
2. Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
3. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
4. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
5. Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Companys Toolbox
6. IMPACT Study Showed Longer Valcyte(R) (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant
7. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
8. New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
9. MitraClip(R) Therapy Data Demonstrate Clinical Benefit in High-Risk Patients With Mitral Regurgitation
10. PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009
11. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- "Australia Capsule Endoscopy Systems ... the Australia Capsule Endoscopy Systems market. The report provides ... and average prices (in US dollars) within market segments: ... , Capsule Endoscopes , Capsule Endoscopy Data ... The report also provides company shares and distribution shares ...
(Date:7/25/2014)... 25, 2014 /PRNewswire-iReach/ -- ScriptPro, of ... Powers Lake, Wisconsin , announce that ... and co-marketing agreement allowing ScriptPro to bring TCGRx ... the United States . ScriptPro is ... workflow systems to retail and ambulatory pharmacies. TCGRx ...
(Date:7/25/2014)... , July 25, 2014 GrowBLOX Sciences, Inc. ... binding Memorandum of Understanding ("MOU") with LaurelCo, LLC, an ... the acquisition of both cultivation and dispensary medical marijuana licenses ... to the MOU, GBLX will acquire a 20% equity interest ... proprietary GrowBLOX TM growing chambers, as well as all ...
Breaking Medicine Technology:Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 3Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 4Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 5ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3
... Texas--(BUSINESS WIRE)--Apr 3, 2007 - Repros,Therapeutics Inc. (NasdaqGM:RPRX) ... of Proellex(TM), an oral drug being developed to,relieve ... with Proellex results in a statistically highly,significant improvement ... well tolerated., Study Details and Results , This ...
... 03, 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today ... Phase 2 trial of GVAX,immunotherapy for prostate ... in 80 patients with metastatic,hormone-refractory prostate cancer ... received the dose that is comparable to ...
Cached Medicine Technology:Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 2Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 3
(Date:7/25/2014)... 2014 The Little Gym of Houston ... Sunday, July 27 at Discovery Green in downtown Houston. ... Katy, Pearland, Friendswood, Spring, The Woodlands, Sugarland-Missouri City, Kingwood, ... , “We’re thrilled to be attending and performing at ... who owns the Sugarland-Missouri City location. “We believe in ...
(Date:7/25/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Ibuprofen and Oxcarbazepine Tablets . , The FDA ... one lot of Oxcarbazepine Tablets, by American Health Packaging (AHP), ... used for the treatment of certain types of seizures in ... recall is that Lot #142588, Expiration Date, 01/2016 of Ibuprofen ...
(Date:7/25/2014)... Ticket Down is a reliable ... in Berkeley at California Memorial Stadium. With the post-World ... football, the organizers of the 2014 Guinness International Champions Cup ... North America. With teams representing La Liga, English Premier League, ... of the best football players from around the world to ...
(Date:7/25/2014)... 2014 On July 22, 2014, ... client and the nation’s number one provider of ... announced their partnership with TransAct Merchant Solutions’ National ... ISO/MSP of Chase Paymentech Solutions, LLC, which provides ... Companies that are members of TransAct’s National Association ...
(Date:7/25/2014)... Hastings and Hastings, a personal injury ... to personal injury claims, announces free initial consultations. Hastings ... services for those that have been injured as a ... Free initial consultation services gives clients’ greater flexibility in ... personal injury claim . It also offers clients the ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3
... A long-running Merck ad featured an older woman with this message: ... be?" and recommended that women ask their doctors about bone ... Merck's drug Fosamax. But this very drug, (generic name alendronate) turned ... the risk of hip fracture from 2 percent to 1 percent, ...
... the time of Chaucer were not dwarfs but only short ... was the case with women more or less, a new ... revealed. ,As part of their study, scientists researched ... upon Humber, North East Lincolnshire, and found that the average ...
... engineered adult stem cells from human umbilical cord blood to ... type 1 diabetes by allowing people to grow their own ... ,The study was conducted by a team of researchers led ... Branch at Galveston. ,As part of the study, ...
... has decided to send youths to learn meditation from Indian ... visit to the war-hit country Thursday with a trip ... the Art of Living Foundation, Iraqi Youth Minister Jasin Mohammed ... of Iraq to Bangalore to undergo the group's Youth Leadership ...
... Abdul Kalam Friday urge the nation's doctors to work for ... Post-Graduate Institute of Medical Sciences in Rohtak, Kalam called upon ... ,If each doctor showed the zeal to treat at ... lot of diseases could be taken care of. ...
... by the American Academy of Neurology finds conventionally recommended ... system Lyme disease. However, there is no compelling ... in treating symptoms that persist following standard therapy. The ... edition of Neurology, the scientific journal of the American ...
Cached Medicine News:Health News:Women Urged to Be Wary of Ads Promoting Unwanted Drugs 2Health News:Women Urged to Be Wary of Ads Promoting Unwanted Drugs 3Health News:Our Medieval Ancestors Were More or Less Similar to Us Than Previously Thought 2Health News:Art of Living Foundation to Train Iraqi Youths 2Health News:Antibiotics Highly Effective for Treating Lyme Disease 2
... provides standardized glare testing. It can be used ... the evaluation of glare disability. For cataract documentation, ... simulate two on-coming halogen car headlights as seen ... can be adjusted to simulate other glare conditions, ...
Aluminum english and metric ruler. 1 3/8 inche wide....
Ruler S/Steel....
At 14 cm point, ruler is bent at 90 degrees angle brought to a blunt point at 15 cm....
Medicine Products: